Skip to main content
OpenTrials
Completed

NCT Number: NCT01710878

Performance and Safety of a Second Generation Antimicrobial Graft in Abdominal Position

Safety and performance of an anti-microbial vascular graft in the treatment of aneurysmal and occlusive disease of the abdominal aorta.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHRU, Angers, France

Loading trial locations.

About this study

The purpose of this multi center, single arm study is to demonstrate the safety and performance of the Second Generation Anti-Microbial (InterGard Synergy) vascular graft in the treatment of aneurismal and occlusive diseases of the abdominal aorta.

The primary endpoint is the assessment of primary and secondary graft patency. The secondary endpoints were the assessment of adverse events and the assessment of triclosan and silver contents in the serum over the time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient aged 18-85 years

Patient presenting with an aorto-iliac occlusion (obstruction of flow) or stenosis, or aorto-iliac aneurysm and eligible for a revascularization with a bifurcated graft

Exclusion criteria

Patient treated as an emergency

Patient included in another investigation

Patient pregnant or lactating or woman of childbearing potential

Patient with a known allergy to the material device used (collagen, triclosan, silver)

Patient with previous aorto-iliac bypass or replacement

Treatment and study plan

Intergard Synergy Graft

Device

Primary outcomes

  1. Primary Graft Patency

    Time frame: Up to 36 months

    Defined as uniterrupted flow with no interventions. Follow-up timeframes - 1, 6, 12, 24, and 36 months

Secondary outcomes

  1. Secondary endpoint - assessment of AEs

    Time frame: Up to 36 months

    Follow-up timeframes - 1, 6, 12, 24, and 36 months

Other outcomes

  1. Secondary endpoint - levels of silver and triclosan

    Time frame: Up to 30 days

    Serum levels prior to surgery, 1 day post-implant, discharge and 30 days

Sponsors and collaborators

Lead sponsor

Maquet Cardiovascular

Industry

Registry information

Official study title

Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in Abdominal Position

Acronym: SYNERGY

Important dates

Study start
2008
Primary completion
2010
Study completion
2012
First posted
Oct 19, 2012
Registry last updated
Nov 26, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.